CRISPR/Cas9-Mediated Correction of the Sickle Mutation in Human CD34+ cells. - Wikidata - wikimedia - TriplyDB

CRISPR/Cas9-Mediated Correction of the Sickle Mutation in Human CD34+ cells.

CRISPR/Cas9-Mediated Correction of the Sickle Mutation in Human CD34+ cells.

http://www.wikidata.org/entity/Q38758476

about

Cellular function reinstitution of offspring red blood cells cloned from the sickle cell disease patient blood post CRISPR genome editing Integrase-Deficient Lentiviral Vector as an All-in-One Platform for Highly Efficient CRISPR/Cas9-Mediated Gene Editing The CRISPR/Cas9 system efficiently reverts the tumorigenic ability of BCR/ABL in vitro and in a xenograft model of chronic myeloid leukemia.Bone Marrow as a Hematopoietic Stem Cell Source for Gene Therapy in Sickle Cell Disease: Evidence from Rhesus and SCD Patients.Emerging cellular and gene therapies for congenital anemias.Gene Therapy for β-Hemoglobinopathies.Therapeutic gene editing: delivery and regulatory perspectives CRISPR-Mediated Integration of Large Gene Cassettes Using AAV Donor Vectors.A Prospective Treatment Option for Lysosomal Storage Diseases: CRISPR/Cas9 Gene Editing Technology for Mutation Correction in Induced Pluripotent Stem Cells.Multiplexed genetic engineering of human hematopoietic stem and progenitor cells using CRISPR/Cas9 and AAV6.The changing landscape of gene editing in hematopoietic stem cells: a step towards Cas9 clinical translation.A Universal Approach to Correct Various HBB Gene Mutations in Human Stem Cells for Gene Therapy of Beta-Thalassemia and Sickle Cell Disease.Recent progress in understanding and manipulating haemoglobin switching for the haemoglobinopathies.Characterization of Gene Alterations following Editing of the β-Globin Gene Locus in Hematopoietic Stem/Progenitor Cells.A Nonhuman Primate Transplantation Model to Evaluate Hematopoietic Stem Cell Gene Editing Strategies for β-Hemoglobinopathies.Molecular engineering of antibodies for site-specific covalent conjugation using CRISPR/Cas9.Marker-free coselection for CRISPR-driven genome editing in human cells.Incorporation of bridged nucleic acids into CRISPR RNAs improves Cas9 endonuclease specificity.Erythropoiesis: insights into pathophysiology and treatments in 2017.Gene Therapy for Hemoglobinopathies

P2860

Q30855717-961CAA81-A315-4D48-BECE-B6E16AD6F3BD Q33655722-C2A43572-3DBC-4164-A88D-B47E60F0B10A Q33688509-BB6D8CC1-2DA1-4650-8A63-D3CC7D02154D Q38817421-0218EBE7-04B3-49C0-BDB5-24D2CB4CFD4B Q38993825-807F9103-18D3-4F96-8B95-3CB58B431AC6 Q39220089-FCE9F035-7B09-4802-AD19-5CC950D55282 Q39230418-F488D959-0E2D-43EE-BDE7-3A1CC89E0E4E Q40116681-680A4665-143A-4B05-92FB-52A5564CF70E Q42226747-27A1FC89-01AF-4070-A566-7F91524A37C3 Q42631262-BEB9E08F-EFF5-4BDB-83A0-85661B673FB7 Q45870741-6A5804F7-1E9D-4B06-8EC3-4D1A1BE0694D Q45874858-3F9CD6A6-4AD1-4881-B8DA-05E42C0B9B71 Q45875308-EE8847E6-8543-43CE-A569-576F9C18C45A Q46676845-95ADEAF6-5BBA-4651-9FBC-45C9B0DBDF3E Q47138237-913F0A30-B8AE-4C9D-950E-3BFF4F0056A2 Q48147422-C5759AEF-6931-4874-976E-3C878D93D8EE Q48266764-9BAA5AB1-9943-46FA-B145-1146FB9F25B5 Q52431554-983FE7E3-0BB7-4690-9F99-FEA3AA269095 Q55436035-EA519FC5-DA03-4CFF-B992-E8EFF3EBF728 Q58795507-67CD8247-1B47-44E4-898F-3582882A2646

P2860

CRISPR/Cas9-Mediated Correction of the Sickle Mutation in Human CD34+ cells.

http://www.wikidata.org/entity/Q38758476

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

CRISPR/Cas9-Mediated Correction of the Sickle Mutation in Human CD34+ cells.

@en

type

label

CRISPR/Cas9-Mediated Correction of the Sickle Mutation in Human CD34+ cells.

@en

prefLabel

CRISPR/Cas9-Mediated Correction of the Sickle Mutation in Human CD34+ cells.

@en

P1433

Q38758476-F756A090-CFB1-4B51-8538-BF64ACD1B392

P1476

Q38758476-EE570090-24C4-41D7-97D6-3361E84F82D7

P2093

Q38758476-0A19EEF3-EBD4-4B82-A1FC-4623FAD048E0

Q38758476-16BD69F3-0308-47D4-8F39-C13195F41FF8

Q38758476-329A7BF2-D025-4551-ACF0-8CA574EBF40B

Q38758476-533A8FC0-3B1F-490E-97F7-2E108F870E5A

Q38758476-53DED542-A163-4C09-9C93-EAF77F774F49

Q38758476-5AD5DB0D-D85F-43E5-835A-78CEC5AFF031

Q38758476-5C9B0337-55DE-40A3-BCFB-A70741A56EA2

Q38758476-864C1308-9358-4284-9886-580306F9675C

Q38758476-8A50C80D-FCF7-432D-B152-E634F7BDDFC4

Q38758476-8BE69292-919A-4118-9488-DCC7C134C66F

P2860

Q38758476-08B028C1-16D1-460A-8877-F60D1F9689E4

Q38758476-0D95BC2B-447F-4B3F-90FA-EFF339FF135D

Q38758476-11D236D2-BA38-4F47-BC38-4056655024FB

Q38758476-15106DC1-63AD-44E0-A086-DAB31CBF2A68

Q38758476-2B8369B8-C2FB-47F5-A532-8D3DB9656F61

Q38758476-2E114EDE-DEBF-4046-AE98-33F47BCC1C24

Q38758476-32A945EE-CA59-4B89-9E3D-8F8D4E48C970

Q38758476-350EB17B-0799-4E78-AB80-F62CFC75400C

Q38758476-355CC079-FEC7-49FA-B6E2-BF782925D887

Q38758476-3F002A27-BA0D-48D6-A4BE-DE6A402E74CA

P304

Q38758476-AF2C5012-FEE8-4D12-BBE5-9B82492ACAB1

P31

Q38758476-DF815B86-A641-4C7C-A384-8BDC1175415F

P356

Q38758476-1AA2D2BB-5860-40B9-A210-61784F6D10AE

P433

Q38758476-46986D1D-E278-4C88-B68C-5D8CA28D521C

P478

Q38758476-38B8B9BA-15BD-415C-9667-78D9BBD55B8B

P50

Q38758476-1D7DF4AA-B141-49D6-B56E-DD8EC1C927BB

Q38758476-3DDCD84B-7DB0-4628-9499-38718AD00905

P577

Q38758476-D900741E-6947-494D-A3E1-C2A6EE2C874F

P698

Q38758476-22FED805-AC9E-4796-A834-0D79EEE74EBD

P921

Q38758476-697A2C2F-B376-47A2-AFEA-7D451B7680F0

Q38758476-72415A05-58C2-4F42-814A-9027CDCB2C5B

P932

Q38758476-71DE5D0F-525F-4150-B665-5A8D72458AC4

P356

P1433

Molecular Therapy

P1476

CRISPR/Cas9-Mediated Correction of the Sickle Mutation in Human CD34+ cells.

@en

P2093

Aaron R Cooper

http://www.w3.org/2001/XMLSchema#string

Beatriz Campo-Fernandez

http://www.w3.org/2001/XMLSchema#string

Carmen F Bjurstrom

http://www.w3.org/2001/XMLSchema#string

Caroline Y Kuo

http://www.w3.org/2001/XMLSchema#string

Courtney S Young

http://www.w3.org/2001/XMLSchema#string

Dianne Lumaquin

http://www.w3.org/2001/XMLSchema#string

Donald B Kohn

http://www.w3.org/2001/XMLSchema#string

Fabrizia Urbinati

http://www.w3.org/2001/XMLSchema#string

Georgia R Lill

http://www.w3.org/2001/XMLSchema#string

Joseph Long

http://www.w3.org/2001/XMLSchema#string

P2860

Genome engineering using the CRISPR-Cas9 system

Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV

Ex vivo generation of fully mature human red blood cells from hematopoietic stem cells

Structure-based redesign of the dimerization interface reduces the toxicity of zinc-finger nucleases

ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering

Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity

Improving CRISPR-Cas nuclease specificity using truncated guide RNAs

High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells

β-globin gene transfer to human bone marrow for sickle cell disease.

CRISPR/Cas9 systems have off-target activity with insertions or deletions between target DNA and guide RNA sequences

P304

1561-1569

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MT.2016.148

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

Matteo Pellegrini

P577

2016-07-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27406980

http://www.w3.org/2001/XMLSchema#string

P921

sickle-cell disease

P932

5113113

http://www.w3.org/2001/XMLSchema#string